TLOG TetraLogic Pharmaceuticals Corporation (CE)

TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 8:40 a.m. Eastern Time in Boston, MA. Mr. Buchi will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting TetraLogic's website at http://ir.tetralogicpharma.com. A replay of the webcast will be available for 10 business days.

About TetraLogic

Tetralogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct.  Birinapant, our clinical-stage product candidate, is currently being tested in Phase 1 and Phase 2 oncology clinical trials for hematological malignancies and multiple solid tumors.

CONTACT: Company Contact:
         Pete A. Meyers
         Chief Financial Officer and Treasurer
         TetraLogic Pharmaceuticals Corporation
         (610) 889-9900, x103
         pete.meyers@tlog.com
         
         Investor Relations Contact:
         Ami Bavishi
         Burns McClellan, Inc.
         (212) 213-0006
         abavishi@burnsmc.com